Leena Gandhi (Dana-Farber via YouTube)

A pi­o­neer­ing im­muno-on­col­o­gy re­searcher heads back to Dana-Far­ber as Eli Lil­ly’s can­cer R&D group un­der­goes a wrench­ing change­up

Leena Gand­hi played a ma­jor role in ex­plor­ing the ther­a­peu­tic po­ten­tial of Keytru­da, Mer­ck’s megas­tar can­cer drug. Six years ago at Dana-Far­ber she mapped out the con­nec­tion be­tween PD-L1 ex­pres­sion and ef­fi­ca­cy in KEYNOTE-001 while lat­er ex­plor­ing the tu­mor mi­croen­vi­ron­ment and the im­pact of chemo com­bi­na­tions on can­cer. And she con­tin­ued her work in im­muno-on­col­o­gy, lead­ing the way on im­por­tant re­search projects and herald­ing a new era in Eli Lil­ly’s can­cer group when she mi­grat­ed to the phar­ma gi­ant 2 years ago.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.